MX2007012947A - Bioenhanced compositions. - Google Patents
Bioenhanced compositions.Info
- Publication number
- MX2007012947A MX2007012947A MX2007012947A MX2007012947A MX2007012947A MX 2007012947 A MX2007012947 A MX 2007012947A MX 2007012947 A MX2007012947 A MX 2007012947A MX 2007012947 A MX2007012947 A MX 2007012947A MX 2007012947 A MX2007012947 A MX 2007012947A
- Authority
- MX
- Mexico
- Prior art keywords
- arb
- composition
- solubility
- solubility enhancing
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to the method of increasing the bioavailability of Angiotensin II Receptor Blockers (ARBs) by preparing a composition of an ARB with at least one solubility enhancing agent. In particular, the present invention relates to solubility enhancing agents that not only act as solubility enhancers but also improve the dissolution rate particularly in acidic or mildly acidic media, where solubility of the ARB is minimal. In the composition, the ARB may be present in the form of physical blend, solid dispersion, solid solution or complex with the solubility enhancing agent. The composition of an ARB with solubility enhancing agent can be incorporated in an immediate release or a controlled release or any other suitable modified release formulation. Immediate release dosage forms containing the composition of an ARB give an in vitro release of at least 40% in acidic media (pH < 3). As a result, the bioavailability of the ARB can be increased by at least 20% as measured by Cmax, AUC0-t and AUCo-a??.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN477MU2005 | 2005-04-18 | ||
IN315MU2006 | 2006-03-06 | ||
PCT/US2006/014422 WO2006113631A2 (en) | 2005-04-18 | 2006-04-18 | Bioenhanced compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007012947A true MX2007012947A (en) | 2008-04-09 |
Family
ID=37115820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007012947A MX2007012947A (en) | 2005-04-18 | 2006-04-18 | Bioenhanced compositions. |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1877042A4 (en) |
JP (1) | JP2008536929A (en) |
KR (1) | KR20080042039A (en) |
AU (1) | AU2006236497A1 (en) |
CA (1) | CA2605183A1 (en) |
IL (1) | IL186721A0 (en) |
MX (1) | MX2007012947A (en) |
WO (1) | WO2006113631A2 (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090123543A1 (en) * | 2006-01-02 | 2009-05-14 | Rubicon Research Private Limited | Pharmaceutical compositions |
AU2007293727A1 (en) * | 2006-09-05 | 2008-03-13 | Astrazeneca Ab | Pharmaceutical composition comprising candesartan cilexetil |
US7923026B2 (en) | 2006-10-20 | 2011-04-12 | Solvay Pharmaceuticals B.V. | Embedded micellar nanoparticles |
EP2083799A1 (en) * | 2006-10-20 | 2009-08-05 | Solvay Pharmaceuticals B.V. | Micellar nanoparticles of chemical substances |
WO2008064338A2 (en) * | 2006-11-22 | 2008-05-29 | Rubicon Research Pvt. Ltd. | Valsartan formulation for pulsatile delivery |
US20100041644A1 (en) * | 2006-11-28 | 2010-02-18 | Laboratorios Liconsa, S. A. | Stabilized solid pharmaceutical composition of candesartan cilexetil |
AR064104A1 (en) * | 2006-12-05 | 2009-03-11 | Novartis Ag | DOSAGE FORMS IN VALSARTAN MICROEMULSION, AND METHODS TO PREPARE THEM |
WO2008076780A2 (en) * | 2006-12-14 | 2008-06-26 | Isp Investments Inc. | Amorphous valsartan and the production thereof |
WO2008084504A2 (en) * | 2007-01-12 | 2008-07-17 | Rubicon Research Private Limited | Pharmaceutical compositions of angiotensin ii receptor blockers |
EP1985287A3 (en) * | 2007-04-25 | 2009-04-29 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical Excipient Complex |
WO2008149338A2 (en) * | 2007-06-06 | 2008-12-11 | Dexcel Ltd. | Process for forming solid oral dosage forms of angiotensin ii receptor antagonists |
RU2010104960A (en) * | 2007-08-01 | 2011-09-10 | Тева Фармасьютикал Индастриес Лтд. (Il) | PHARMACEUTICAL COMPOSITION OF CANDESARTAN |
KR20100091963A (en) * | 2007-10-09 | 2010-08-19 | 노파르티스 아게 | Pharmaceutical formulation of valsartan |
AU2008313620A1 (en) * | 2007-10-19 | 2009-04-23 | Abbott Gmbh & Co. Kg | Solid dispersion product containing N-aryl urea-based compound |
JP5222550B2 (en) * | 2007-12-27 | 2013-06-26 | 財團法人工業技術研究院 | Sustained release composition and method for producing the same |
WO2009084040A1 (en) * | 2007-12-28 | 2009-07-09 | Rubicon Research Private Limited | Once a day formulation of angiotensin receptor blockers |
RU2010139567A (en) * | 2008-02-28 | 2012-04-10 | Новартис АГ (CH) | VALSARTAN-CONTAINING SOLID ORAL MEDICINAL FORMS AND METHODS FOR THEIR PRODUCTION |
EP2285358A1 (en) * | 2008-06-03 | 2011-02-23 | Novartis AG | Pulsatile release of valsartan |
SI2165702T1 (en) | 2008-09-17 | 2012-05-31 | Helm Ag | Stable and readily dissolved compositions of candesartan cilexetil prepared with wet granulation |
DE102008047910A1 (en) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tabletting excipient based on lactose and cellulose |
WO2010151080A2 (en) * | 2009-06-25 | 2010-12-29 | 진양제약 주식회사 | Pharmaceutical composition containing carboxylosartan and a production method therefor |
WO2011028016A2 (en) * | 2009-09-04 | 2011-03-10 | 한올바이오파마주식회사 | Pharmaceutical preparation comprising beta-adrenergic blockers and angiotensin ii receptor blockers |
MX356727B (en) * | 2012-02-08 | 2018-06-12 | Supernus Pharmaceuticals Inc | Modified release formulations of viloxazine. |
WO2014088123A1 (en) * | 2012-12-05 | 2014-06-12 | Sawai Pharmaceutical Co., Ltd. | Candesartan cilexetil-containing preparation |
EP2952187A4 (en) | 2013-01-30 | 2016-08-17 | Sawai Seiyaku Kk | Pharmaceutical composition containing candesartan cilexetil |
WO2016005994A2 (en) * | 2014-07-06 | 2016-01-14 | Gattefosse India Pvt. Ltd. | Pharmaceutical composition comprising solid dispersion of bcs class ii drugs with gelucires |
US9675585B1 (en) | 2016-03-24 | 2017-06-13 | Ezra Pharma | Extended release pharmaceutical formulations |
US9687475B1 (en) | 2016-03-24 | 2017-06-27 | Ezra Pharma Llc | Extended release pharmaceutical formulations with controlled impurity levels |
AU2018345647A1 (en) | 2017-10-04 | 2020-04-16 | Celgene Corporation | Compositions and methods of use of cis-4-(2-{((3S,4R)-3-fluorooxan-4-yl) amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide |
CN109350609A (en) * | 2018-11-14 | 2019-02-19 | 常州大学 | A kind of preparation of chitosan package zeins nanoparticle and the application for loading acacetin sodium salt |
CN113933472A (en) * | 2020-06-29 | 2022-01-14 | 武汉武药科技有限公司 | Dissolution medium for determining dissolution rate of telmisartan solid preparation and application thereof |
CN112516105A (en) * | 2020-12-10 | 2021-03-19 | 成都恒瑞制药有限公司 | Losartan potassium oral preparation and preparation method thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
JP3751287B2 (en) * | 2002-03-27 | 2006-03-01 | バイエル薬品株式会社 | Miniaturized nifedipine nucleated tablets |
EP1575581A1 (en) * | 2002-12-18 | 2005-09-21 | Novartis AG | Combinations of valsartan with cox-2 inhibitors |
US20050096365A1 (en) * | 2003-11-03 | 2005-05-05 | David Fikstad | Pharmaceutical compositions with synchronized solubilizer release |
HRP20031029A2 (en) * | 2003-12-12 | 2005-08-31 | Belupo - Lijekovi I Kozmetika D.D. | Process for production of inclusion complexes of valsartan with?-cylodextrin |
-
2006
- 2006-04-18 JP JP2008507777A patent/JP2008536929A/en active Pending
- 2006-04-18 WO PCT/US2006/014422 patent/WO2006113631A2/en active Application Filing
- 2006-04-18 EP EP06750455A patent/EP1877042A4/en not_active Withdrawn
- 2006-04-18 CA CA002605183A patent/CA2605183A1/en not_active Abandoned
- 2006-04-18 AU AU2006236497A patent/AU2006236497A1/en not_active Abandoned
- 2006-04-18 MX MX2007012947A patent/MX2007012947A/en unknown
- 2006-04-18 KR KR1020077026647A patent/KR20080042039A/en not_active Application Discontinuation
-
2007
- 2007-10-17 IL IL186721A patent/IL186721A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1877042A4 (en) | 2011-03-02 |
JP2008536929A (en) | 2008-09-11 |
IL186721A0 (en) | 2008-02-09 |
EP1877042A2 (en) | 2008-01-16 |
AU2006236497A1 (en) | 2006-10-26 |
WO2006113631A2 (en) | 2006-10-26 |
CA2605183A1 (en) | 2006-10-26 |
KR20080042039A (en) | 2008-05-14 |
WO2006113631A3 (en) | 2006-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007012947A (en) | Bioenhanced compositions. | |
BRPI0910182A2 (en) | compound of formula (i), pharmaceutical composition, method of treating a disorder and use of a compound " | |
UA94052C2 (en) | Pyridazine derivatives | |
GEP20125628B (en) | Pharmaceutical compositions containing antagonist anti-cd40 antibody | |
IN2012DN03180A (en) | ||
MX2010002191A (en) | Compositions and methods employing nmda antagonists for achieving an anesthetic-sparing effect. | |
WO2007145991A3 (en) | Anti-inflammatory and analgesic compositions and related methods | |
UA104869C2 (en) | Normal;heading 1;heading 2;heading 3;PHARMACEUTICAL FORMULATIONS CONTAINING DOPAMINE RECEPTOR LIGANDS | |
MX2007013065A (en) | Dihydrobenzofuran derivatives and uses thereof. | |
UA107649C2 (en) | Isoxazole-ligands of metabotropic glutamate receptor and their use as potentiator | |
TW200626558A (en) | Indazolone derivatives | |
UA95798C2 (en) | Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
EA018193B3 (en) | Compounds and pharmaceutical compositions for reducing uric acid level | |
MX2009003246A (en) | Analogs of ghrelin substituted at the n-terminal. | |
DK2041133T3 (en) | Derivatives of imadazole [1,2-A] pyridine-2-carboxamides, their preparation and their use in therapeutics | |
MY143568A (en) | 11b-hsd1 inhibitors for the treatment of diabetes | |
MY161620A (en) | Oral care formulations that enhance amount of soluble zinc | |
EA201170289A1 (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AT LOW CONCENTRATION OF IMPURITIES | |
PL2120890T3 (en) | Coated pellets | |
IN2012DN00954A (en) | ||
UA96994C2 (en) | Derivatives of 7-alkynyl-1,8-naphthyridones, method of the preparation and use thereof | |
MX2009005984A (en) | High protein concentration formulations containing mannitol. | |
GEP20146061B (en) | Glucocorticoid receptor agonist composed of 2,2,4-trimethyl-6-phenyl- 1,2-dihydroquinoline derivative having substituted oxy group | |
SI2165702T1 (en) | Stable and readily dissolved compositions of candesartan cilexetil prepared with wet granulation | |
ZA200705949B (en) | Fabric conditioning compositions |